Literature DB >> 6430313

Pharmacokinetics of valproic acid in the elderly.

E Perucca, R Grimaldi, G Gatti, S Pirracchio, F Crema, G M Frigo.   

Abstract

The kinetics of a single oral dose of sodium valproate was studied in six healthy elderly patients (age 68-89 years) and six young control subjects (age 24-26 years). The profiles of total plasma valproic acid (VPA) concentrations were very similar in the elderly and in the young. Half-lives (15.3 +/- 0.7 s.e. mean in the elderly vs 13.0 +/- 1.0 h in the young), volumes of distribution (0.16 +/- 0.01 l/kg in the elderly vs 0.14 +/- 0.01 l/kg in the young) and clearance (7.5 +/- 0.9 ml h-1 kg-1 in the elderly vs 7.7 +/- 0.6 ml h-1 kg-1 in the young) did not differ significantly between the two groups. Free VPA concentrations were significantly increased in the elderly. The clearance of the free drug (intrinsic clearance) was reduced from 127.0 +/- 12 ml h-1 kg-1 (control value in the young) to 77.7 +/- 5.5 ml h-1 kg-1 (P less than 0.02). Free VPA fraction was 9.5 +/- 0.6% in the elderly and 6.6 +/- 0.5% in the young (P less than 0.02). These findings suggest that the pharmacokinetic alterations of VPA in old age are complex and include at least two separate mechanisms: a decrease in plasma protein binding and a reduction of drug metabolizing capacity resulting in decreased clearance of free drug by the liver.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6430313      PMCID: PMC1463439          DOI: 10.1111/j.1365-2125.1984.tb02401.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Clinical pharmacology: drugs and the elderly.

Authors:  L E Ramsay; G T Tucker
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-10

Review 3.  Clinical pharmacokinetics of valproic acid.

Authors:  R Gugler; G E von Unruh
Journal:  Clin Pharmacokinet       Date:  1980 Jan-Feb       Impact factor: 6.447

Review 4.  Monitoring of free valproic acid levels?

Authors:  R H Levy
Journal:  Ther Drug Monit       Date:  1980       Impact factor: 3.681

Review 5.  Drug therapy: drug disposition in old age.

Authors:  D J Greenblatt; E M Sellers; R I Shader
Journal:  N Engl J Med       Date:  1982-05-06       Impact factor: 91.245

6.  Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

7.  Disposition of sodium valproate in epileptic patients.

Authors:  E Perucca; G Gatti; G M Frigo; A Crema; S Calzetti; D Visintini
Journal:  Br J Clin Pharmacol       Date:  1978-06       Impact factor: 4.335

8.  Pharmacokinetics of valproic acid in young and elderly subjects.

Authors:  S M Bryson; N Verma; P J Scott; P C Rubin
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

9.  Plasma protein-binding and CSF concentrations of valproic acid in man following acute oral dosing.

Authors:  W G Rapeport; A D Mendelow; G French; P MacPherson; E Teasdale; E Agnew; G G Thompson; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

10.  Free fraction of valproic acid: in vitro time-dependent increase and correlation with free fatty acid concentration in human plasma and serum.

Authors:  F Albani; R Riva; G Procaccianti; A Baruzzi; E Perucca
Journal:  Epilepsia       Date:  1983-02       Impact factor: 5.864

  10 in total
  26 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

3.  The 'apparent clearance' of free phenytoin in elderly vs. younger adults.

Authors:  Daniel F B Wright; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

4.  Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.

Authors:  R L Smith; T Haslemo; H Refsum; E Molden
Journal:  Eur J Clin Pharmacol       Date:  2016-06-29       Impact factor: 2.953

Review 5.  Treatment recommendations for anticonvulsant drug therapy in the older patient.

Authors:  P D Swanson
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

6.  AED Treatment Through Different Ages: As Our Brains Change, Should Our Drug Choices Also?

Authors:  Jacqueline A French; Brigid A Staley
Journal:  Epilepsy Curr       Date:  2012-07       Impact factor: 7.500

Review 7.  Anticonvulsant therapy in aged patients. Clinical pharmacokinetic considerations.

Authors:  I Bernus; R G Dickinson; W D Hooper; M J Eadie
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 8.  Plasma protein binding of drugs in the elderly.

Authors:  S M Wallace; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

Review 9.  Drug treatment of epilepsy in elderly people: focus on valproic Acid.

Authors:  Linda J Stephen
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 10.  Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience.

Authors:  Emilio Perucca
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.